Von Willebrand factor for the liver: Friend or foe?
Qing Pang, Huichun Liu, Hao Jin, Lei Zhou, Zhongran Man – 29 January 2018
Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease
Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole – 29 January 2018 – The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon‐free DAA treatment on all‐cause mortality in hepatitis C virus–infected patients without advanced liver disease.
A novel frailty index improves risk prediction of waitlist mortality over the model for end‐stage liver disease score alone
Heng Fan, Jian‐hua Zhu – 29 January 2018
Reply
Jennifer C. Lai, Kenneth E. Covinsky, Jennifer L. Dodge, W. John Boscardin, Dorry L. Segev, John P. Roberts, Sandy Feng – 29 January 2018
Issue Information
29 January 2018
Issue Information
29 January 2018
Farnesoid X receptor signaling activates the hepatic X‐box binding protein 1 pathway in vitro and in mice
Xiaoying Liu, Grace L. Guo, Bo Kong, David B. Hilburn, Susan C. Hubchak, Seong Park, Brian LeCuyer, Antony Hsieh, Li Wang, Deyu Fang, Richard M. Green – 29 January 2018 – Bile acids are endogenous ligands of the nuclear receptor, farnesoid X receptor (FXR), and pharmacological FXR modulators are under development for the treatment of several liver disorders. The inositol‐requiring enzyme 1α/X‐box binding protein 1 (IRE1α/XBP1) pathway of the unfolded protein response (UPR) is a protective cellular signaling pathway activated in response to endoplasmic reticulum (ER) stress.
Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease
Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole – 29 January 2018 – The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon‐free DAA treatment on all‐cause mortality in hepatitis C virus–infected patients without advanced liver disease.
Liver atrophy and regeneration in noncirrhotic portal vein thrombosis: Effect of surgical shunts
Abdulrhman S. Elnaggar, Adam D. Griesemer, Stuart Bentley‐Hibbert, Robert S. Brown, Mercedes Martinez, Steven J. Lobritto, Tomoaki Kato, Jean C. Emond – 29 January 2018 – The goal of the study is to characterize the relationship between portal vein thrombosis (PVT) and hepatic atrophy in patients without cirrhosis and the effect of various types of surgical shunts on liver regeneration and splenomegaly. Patients without cirrhosis with PVT suffer from presinusoidal portal hypertension, and often hepatic atrophy is a topic that has received little attention.
All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
Juan Berenguer, Ángela Gil‐Martin, Inmaculada Jarrin, Ana Moreno, Lourdes Dominguez, Marisa Montes, Teresa Aldámiz‐Echevarría, María J. Téllez, Ignacio Santos, Laura Benitez, José Sanz, Pablo Ryan, Gabriel Gaspar, Beatriz Alvarez, Juan E. Losa, Rafael Torres‐Perea, Carlos Barros, Juan V. San Martin, Sari Arponen, María T. de Guzmán, Raquel Monsalvo, Ana Vegas, María T. Garcia‐Benayas, Regino Serrano, Luis Gotuzzo, María Antonia Menendez, Luis M Belda, Eduardo Malmierca, María J. Calvo, Encarnación Cruz‐Martos, Juan J.